New opportunities for preventive anti-inflammatory therapy in the management of patients with moderate and severe COVID-19

The specific feature of new coronavirus infection (COVID-19) is high risk of hyperinflammatory response or cytokine storm development, which underly the pathogenesis of several life-threatening conditions and determine the disease outcomes. Pathophysiological features of COVID-19 justify the search of effective drugs capable to control the hyperinflammatory response.

Aim. To evaluate the efficacy and safety of Aterixen^® (1-[2-(1-Мethylimidazol-4-yl)-ethyl]perhydroazin-2,6-dion) for achieving clinical improvement in adult patients hospitalized with moderate and severe COVID-19.

Materials and methods. Multicenter, adaptive, randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of Aterixen^® , tablets, 100 mg, in patients with COVID-19. The study analysis included 116 patients who, by randomization, were divided into 2 groups: 57 patients were included in the Aterixen^® drug group and 59 patients were in the placebo group.

Results and conclusion. Obtained results have shown high efficacy and statistically significant superiority of Aterixen^® over placebo. Thus, it allows us to consider it as viable medication for COVID-19 pathogenetic therapy.